Merck & Company (MRK) 62.30 $MRK
Merck seeks new OK for cancer drug, reorganization on track
BY LINDA A. JOHNSON - AP - 29 mins ago
TRENTON, N.J. (AP) — Drugmaker Merck & Co. is ratcheting up its race with rival Bristol-Myers Squibb Co. for leadership in one of today's hottest research areas, immuno-oncology, which harnesses the immune system to fight cancer.
MRK: 62.30 (-0.26), BMY: 62.18 (+1.86)
Interesting February Stock Options for MRK
StockOptionsChannel.com - Mon Jan 12, 11:07AM CST
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc . So this week we highlight one interesting put contract, and one interesting call contract, from the...
MRK: 62.30 (-0.26)
I'm Expecting Some Very Positive News Flow From Gilead
Brian Nelson - at Seeking Alpha - Mon Jan 12, 10:55AM CST
JNJ: 104.58 (-0.36), ABT: 45.58 (+0.38), VRTX: 118.31 (-3.90), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), ACHN: 14.64 (+0.08), MRK: 62.30 (-0.26), CVS: 97.20 (-0.72), ABBV: 65.76 (-0.02), ENTA: 49.41 (-0.70)
Global Orphan Drug Pipeline & Regulatory Insight 2015
M2 - Mon Jan 12, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/55b8nr/global_orphan) has announced the addition of the "Global Orphan Drug Pipeline & Regulatory Insight 2015" report to their offering. Owing to the pharmaceutical companies' inadequate interest in this category of drugs, the term orphan was coined for drugs targeted to treat rare diseases. Almost 222 orphan designated drugs in US and 132 in Europe are marketed till date. However, in spite of the increased efforts in this market, there is still a shortage in the number of treatments for most rare disease indications. Thus, the market for rare diseases in the United States, Europe and other regions continue to offer significant potential for growth owing to enormous unmet medical need. The US and European region are the major markets for orphan drugs. It is in these two regions that the popularity of these drugs and diseases is increasing rapidly. The US alone accounts for a dominating share of 55%-60% in the global pie, followed by Europe. As the Asian pharmaceutical markets are still in nascent stage, there opportunities for orphan drugs in Asia are also immense and getting increasingly popular. It is expected that by 2017-18, the Asian orphan drugs market would witness steady growth. Global Orphan Drug Pipeline & Regulatory Insight 2015 Report Highlights & Findings: - Europe Orphan Drug Clinical Pipeline: 697 Drugs - Majority Orphan Designated Drugs in Phase-II : 249 - Globally Marketed Orphan Drugs: 274 Key Topics Covered: 1. What Are Orphan Drugs? 2. Global Orphan Drug Market Outlook 3. Orphan Drug Designation Criteria 4. Reimbursement Policy For Orphan Drug 5. US (FDA) Regulatory Framework For Orphan Drugs 6. Europe (EMA) Regulatory Framework For Orphan Drugs 7. Asia Regulatory Framework For Orphan Drugs 8. Global Orphan Drug Pipeline by Company, Country, Indication & Phase 9. Marketed Orphan Drug by Company, Country & Indication 10. Discontinued & Suspended Orphan Drugs in Clinical Trials 11. Competitive Landscape - AOP Orphan - Agenus - Alexion - Bristol Myers Squibb - Biogen Idec - Celgene - Eli Lilly - Genethon - Genzyme Corporation - Glaxosmithkline - Merck - Novartis Pharmaceuticals - Orphan Europe - Pfizer - Prosensa - Rare Disease Therapeutics - Roche - Sanofi - Shire - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/55...bal_orphan
BIIB: 347.84 (+5.50), MRK: 62.30 (-0.26), LLY: 69.42 (-0.51), NVS: 95.48 (-0.64), CELGZ: 3.41 (+0.13)
Europe Orphan Drug Market & Clinical Trial Insight 2015
M2 - Mon Jan 12, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/vlb6wg/europe_orphan) has announced the addition of the "Europe Orphan Drug Market & Clinical Trial Insight 2015" report to their offering. It has been estimated that Europe has witnessed more than 100 therapies for rare diseases being approved since 2000, when the European Commission introduced incentives to encourage the development of these drugs. The share of R&D for orphan medicinal products development as a proportion of total biopharmaceutical industry's R&D has been increasing significantly over the years. This is strengthened by the fact that almost all companies which have been set up recently to develop orphan medicinal products have their extensive R&D plants and staff located in the European Union. This shows the significance of the region and its level of attractiveness. Additionally, the investment in R&D by the European companies for developing orphan medicinal products has increased by more than 200%, while the total number of employees in these companies has recorded an increase of more than 150% since 2000. With the long durations of lead times in the biopharmaceuticals industry for R&D projects, it is most likely that the EU Regulation for Orphan medicinal products would have a significant impact in the coming years. Europe Orphan Drug Market & Clinical Trial Insight 2015 Report Highlights & Findings: - Europe Orphan Drug Market Overview - In-depth Insight on Regulatory Framework & for Orphan Drugs - Application Procedure for Seeking Orphan Drug Status - Comprehensive Insight on Orphan Drug Clinical Pipeline - Europe Orphan Drug Clinical Pipeline: 326 Drugs - Majority Orphan Designated Drugs in Phase-II : 111 - Marketed Orphan Drugs in Europe: 130 Key Topics Covered: 1. What Are Orphan Drugs? 2. Europe Orphan Drug Designation Criteria 3. Europe Orphan Drug Reimbursement Policy 4. Europe Orphan Drug Market Overview 5. Europe Regulatory Framework for Orphan Drugs 6. Europe Orphan Drug Pipeline by Country, Company, Indication & Phase 7. Marketed Orphan Drug in Europe by Country, Company & Indication 8. Discontinued & Suspended Orphan Drug Clinical Pipeline 9. Competitive Landscape - AOP Orphan - Genethon - Genzyme Corporation - Glaxosmithkline - Merck - Novartis Pharmaceuticals - Orphan Europe - Pfizer - Prosensa - Shire - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/vl...ope_orphan
MRK: 62.30 (-0.26), NVS: 95.48 (-0.64)
Global Venlafaxine Industry Report 2015-2020
M2 - Mon Jan 12, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/bzskl2/global) has announced the addition of the "Global Venlafaxine Industry Report 2014" report to their offering. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The venlafaxine market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Venlafaxine industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on twenty-one industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The venlafaxine industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Venlafaxine Industry Overview - Global Venlafaxine Market Status Analysis - Major Regions Venlafaxine Market Status Analysis - Major Countries Venlafaxine Market Status and Analysis - Major Companies Venlafaxine Market Status and Analysis - Venlafaxine Industry Chain and Marketing Channels Analysis - Venlafaxine Industry Segment Market Analysis - Venlafaxine Industry Development Trend - Venlafaxine New Project Investment Feasibility Analysis - Global Venlafaxine Industry Research Conclusions Companies Mentioned - Abbott Laboratories - Amgen - Astellas - Astrazeneca - Bayer - Boehringer-Ingelheim - Bristol-Myers Squibb - Eisai - Eli Lilly Inc - Genentech - Glaxosmithkline - Johnson & Johnson - Kanghong Pharmaceutical - Merck - Novartis - Otsuka - Pfize - Roche Group - Sanofi-Aventis - Shuaike - Takeda For more information visit http://www.researchandmarkets.com/research/bzskl2/global
JNJ: 104.58 (-0.36), ABT: 45.58 (+0.38), MRK: 62.30 (-0.26), AMGN: 156.22 (+0.49), LLY: 69.42 (-0.51), BMY: 62.18 (+1.86), NVS: 95.48 (-0.64)
Merck (MRK) Stock Higher Today as It Speeds Plans to Submit New Drugs
at The Street - Mon Jan 12, 6:52AM CST
The drug maker accelerates plans to submit new drugs for hepatitis C and lung cancer for regulatory approval to close the gap with competitors in two lucrative segments.
MRK: 62.30 (-0.26)
Advaxis Provides 2014 Year-End Review and 2015 Outlook
GlobeNewswire - Mon Jan 12, 6:30AM CST
Multiple Clinical Milestones Anticipated in 2015 Involving Lm-LLO Cancer Immunotherapy Pipeline
ADXS: 12.09 (+0.79), MRK: 62.30 (-0.26), PETX: 18.67 (+0.07)
Merck accelerates regulatory submission plans in cancer and hepatitis
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 6:13AM CST
MRK: 62.30 (-0.26)
Bristol-Myers Checkpoint Inhibitor Prolongs Lung Cancer Patient Survival
at The Street - Mon Jan 12, 6:07AM CST
Lung cancer is a larger commercial market opportunity for Bristol's Opdivo and Merck's Keytruda.
MRK: 62.30 (-0.26), BMY: 62.18 (+1.86)
Merck Provides Update on Strategic Actions to Transform the Company and Build a Platform for Sustained Future Growth at the 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 12, 6:00AM CST
--Company Expects to Submit sBLA for KEYTRUDA in Mid-Year 2015 for Advanced Non-Small Cell Lung Cancer
JPM: 58.83 (-0.51), MRK: 62.30 (-0.26)
Neviah Genomics Achieves Key Development Milestone for PropheTox(TM) Bioassay for Early Prediction of Drug-Induced Liver Toxicity and Secures Additional Financing
Business Wire - Mon Jan 12, 6:00AM CST
Neviah Genomics announced today that it had discovered and experimentally validated a set of biomarkers for the early detection of chronic drug-induced liver toxicity. Based on these results, the company is moving toward the further development of its PropheTox(TM) Bioassay, targeting 2016 for its commercial introduction. Neviah Genomics was jointly established in 2012 by Merck Serono, the biopharmaceutical business of Merck, and Compugen, and is operating from MS Ventures' Israel Bioincubator in Yavne, Israel.
MRK: 62.30 (-0.26), CGEN: 9.26 (-0.03)
Bristol-Myers stops cancer trial early after Opdivo meets efficacy endpoint
Seeking Alpha - at Seeking Alpha - Sun Jan 11, 9:29PM CST
MDVN: 104.39 (+0.90), AZN: 70.79 (+1.35), MRK: 62.30 (-0.26), BMY: 62.18 (+1.86), CELG: 117.00 (+3.33), FPRX: 28.00 (+3.09)
5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 101.95 (-1.68), ACT: 272.28 (+3.60), AMGN: 156.22 (+0.49), RGLS: 18.90 (-0.43), EPZM: 17.49 (+0.01), ALKS: 68.61 (+3.47), HSP: 61.55 (-0.09), CELG: 117.00 (+3.33), JNJ: 104.58 (-0.36), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), ACHN: 14.64 (+0.08), MRK: 62.30 (-0.26), ABBV: 65.76 (-0.02), AGIO: 131.55 (+3.43), XLRN: 40.89 (-0.25), NVS: 95.48 (-0.64)
3 Ways Gilead Sciences, Inc. Could Still Be in Big Trouble
Sean Williams, The Motley Fool - Motley Fool - Sun Jan 11, 8:02AM CST
Arguably no biotech stock thrilled investors in 2014 more than Gilead Sciences . Gilead finished the year up 26%, about double the performance of the broad-market indexes, and the approval and exceptional launch of hepatitis C drugs Sovaldi and...
VRTX: 118.31 (-3.90), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), MRK: 62.30 (-0.26), AZN: 70.79 (+1.35), ABBV: 65.76 (-0.02)
3 Clinical-Stage Biotech Stocks with Explosive Upside Potential in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Jan 10, 1:07PM CST
Source: Flickr via Idaho National Laboratory. Biotech stocks have the uncanny ability to absolutely crush it following a positive clinical or regulatory catalyst. And this trend has been especially pronounced among standout clinical-stage...
BLUE: 101.95 (-1.68), DVAX: 18.58 (+0.87), HTGC: 14.70 (+0.12), NVAX: 6.41 (+0.10), PFE: 32.77 (+0.12), MRK: 62.30 (-0.26), AZN: 70.79 (+1.35), CLDN: 18.35 (-0.25), GSK: 42.93 (+0.13)
Can You Guess the Most Common Reason People Visit the Doctor?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 10, 6:14AM CST
Source: Flickr user Rusty Ferguson The Affordable Care Act, the health reform law better known as Obamacare, is quickly changing the medical care landscape. Gone are the days when insurers could deny coverage for preexisting conditions; now there...
MRK: 62.30 (-0.26), AMGN: 156.22 (+0.49), LLY: 69.42 (-0.51), BMY: 62.18 (+1.86)
Why Cubist Pharmaceuticals Inc. Stock Skyrocketed 33% in December
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 09, 1:02PM CST
What: Shares of Cubist Pharmaceuticals , a biopharmaceutical company focused on developing drugs to be used in the acute-care environment, skyrocketed 33% in December, based on data from S&P Capital IQ , after agreeing to be purchased by ...
CBST: 100.77 (+0.02), MRK: 62.30 (-0.26)
2015 Dogs of the Dow: 10 Dividend Stocks You Should Watch This Year
Dan Caplinger, The Motley Fool - Motley Fool - Fri Jan 09, 1:00PM CST
Source: Wikimedia Commons, courtesy Geo Swan. In recent years, investors have discovered the immense value of dividend-paying stocks, which have been one of the few reliable sources of portfolio income in a low-interest-rate environment that has...
KO: 42.64 (-0.39), GE: 23.98 (-0.05), PFE: 32.77 (+0.12), XOM: 90.33 (-1.77), INTC: 36.60 (-0.16), T: 33.49 (+0.09), MRK: 62.30 (-0.26), MCD: 93.01 (-0.20), CAT: 86.89 (-0.76), CVX: 105.88 (-2.33), MSFT: 46.60 (-0.59), VZ: 47.08 (+0.32), CSCO: 28.05 (+0.26)
FDA approves new blood thinner from Japanese drugmaker
AP - Fri Jan 09, 9:38AM CST
WASHINGTON (AP) — The Food and Drug Administration has approved a new blood thinner from a Japanese drugmaker to reduce stroke and blood clots in patients with a common irregular heartbeat.
JNJ: 104.58 (-0.36), PFE: 32.77 (+0.12), MRK: 62.30 (-0.26), BMY: 62.18 (+1.86)
Merck seeks new OK for cancer drug, reorganization on track
BY LINDA A. JOHNSON - AP - 29 mins ago
TRENTON, N.J. (AP) — Drugmaker Merck & Co. is ratcheting up its race with rival Bristol-Myers Squibb Co. for leadership in one of today's hottest research areas, immuno-oncology, which harnesses the immune system to fight cancer.
MRK: 62.30 (-0.26), BMY: 62.18 (+1.86)
Interesting February Stock Options for MRK
StockOptionsChannel.com - Mon Jan 12, 11:07AM CST
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc . So this week we highlight one interesting put contract, and one interesting call contract, from the...
MRK: 62.30 (-0.26)
I'm Expecting Some Very Positive News Flow From Gilead
Brian Nelson - at Seeking Alpha - Mon Jan 12, 10:55AM CST
JNJ: 104.58 (-0.36), ABT: 45.58 (+0.38), VRTX: 118.31 (-3.90), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), ACHN: 14.64 (+0.08), MRK: 62.30 (-0.26), CVS: 97.20 (-0.72), ABBV: 65.76 (-0.02), ENTA: 49.41 (-0.70)
Global Orphan Drug Pipeline & Regulatory Insight 2015
M2 - Mon Jan 12, 10:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/55b8nr/global_orphan) has announced the addition of the "Global Orphan Drug Pipeline & Regulatory Insight 2015" report to their offering. Owing to the pharmaceutical companies' inadequate interest in this category of drugs, the term orphan was coined for drugs targeted to treat rare diseases. Almost 222 orphan designated drugs in US and 132 in Europe are marketed till date. However, in spite of the increased efforts in this market, there is still a shortage in the number of treatments for most rare disease indications. Thus, the market for rare diseases in the United States, Europe and other regions continue to offer significant potential for growth owing to enormous unmet medical need. The US and European region are the major markets for orphan drugs. It is in these two regions that the popularity of these drugs and diseases is increasing rapidly. The US alone accounts for a dominating share of 55%-60% in the global pie, followed by Europe. As the Asian pharmaceutical markets are still in nascent stage, there opportunities for orphan drugs in Asia are also immense and getting increasingly popular. It is expected that by 2017-18, the Asian orphan drugs market would witness steady growth. Global Orphan Drug Pipeline & Regulatory Insight 2015 Report Highlights & Findings: - Europe Orphan Drug Clinical Pipeline: 697 Drugs - Majority Orphan Designated Drugs in Phase-II : 249 - Globally Marketed Orphan Drugs: 274 Key Topics Covered: 1. What Are Orphan Drugs? 2. Global Orphan Drug Market Outlook 3. Orphan Drug Designation Criteria 4. Reimbursement Policy For Orphan Drug 5. US (FDA) Regulatory Framework For Orphan Drugs 6. Europe (EMA) Regulatory Framework For Orphan Drugs 7. Asia Regulatory Framework For Orphan Drugs 8. Global Orphan Drug Pipeline by Company, Country, Indication & Phase 9. Marketed Orphan Drug by Company, Country & Indication 10. Discontinued & Suspended Orphan Drugs in Clinical Trials 11. Competitive Landscape - AOP Orphan - Agenus - Alexion - Bristol Myers Squibb - Biogen Idec - Celgene - Eli Lilly - Genethon - Genzyme Corporation - Glaxosmithkline - Merck - Novartis Pharmaceuticals - Orphan Europe - Pfizer - Prosensa - Rare Disease Therapeutics - Roche - Sanofi - Shire - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/55...bal_orphan
BIIB: 347.84 (+5.50), MRK: 62.30 (-0.26), LLY: 69.42 (-0.51), NVS: 95.48 (-0.64), CELGZ: 3.41 (+0.13)
Europe Orphan Drug Market & Clinical Trial Insight 2015
M2 - Mon Jan 12, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/vlb6wg/europe_orphan) has announced the addition of the "Europe Orphan Drug Market & Clinical Trial Insight 2015" report to their offering. It has been estimated that Europe has witnessed more than 100 therapies for rare diseases being approved since 2000, when the European Commission introduced incentives to encourage the development of these drugs. The share of R&D for orphan medicinal products development as a proportion of total biopharmaceutical industry's R&D has been increasing significantly over the years. This is strengthened by the fact that almost all companies which have been set up recently to develop orphan medicinal products have their extensive R&D plants and staff located in the European Union. This shows the significance of the region and its level of attractiveness. Additionally, the investment in R&D by the European companies for developing orphan medicinal products has increased by more than 200%, while the total number of employees in these companies has recorded an increase of more than 150% since 2000. With the long durations of lead times in the biopharmaceuticals industry for R&D projects, it is most likely that the EU Regulation for Orphan medicinal products would have a significant impact in the coming years. Europe Orphan Drug Market & Clinical Trial Insight 2015 Report Highlights & Findings: - Europe Orphan Drug Market Overview - In-depth Insight on Regulatory Framework & for Orphan Drugs - Application Procedure for Seeking Orphan Drug Status - Comprehensive Insight on Orphan Drug Clinical Pipeline - Europe Orphan Drug Clinical Pipeline: 326 Drugs - Majority Orphan Designated Drugs in Phase-II : 111 - Marketed Orphan Drugs in Europe: 130 Key Topics Covered: 1. What Are Orphan Drugs? 2. Europe Orphan Drug Designation Criteria 3. Europe Orphan Drug Reimbursement Policy 4. Europe Orphan Drug Market Overview 5. Europe Regulatory Framework for Orphan Drugs 6. Europe Orphan Drug Pipeline by Country, Company, Indication & Phase 7. Marketed Orphan Drug in Europe by Country, Company & Indication 8. Discontinued & Suspended Orphan Drug Clinical Pipeline 9. Competitive Landscape - AOP Orphan - Genethon - Genzyme Corporation - Glaxosmithkline - Merck - Novartis Pharmaceuticals - Orphan Europe - Pfizer - Prosensa - Shire - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/vl...ope_orphan
MRK: 62.30 (-0.26), NVS: 95.48 (-0.64)
Global Venlafaxine Industry Report 2015-2020
M2 - Mon Jan 12, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/bzskl2/global) has announced the addition of the "Global Venlafaxine Industry Report 2014" report to their offering. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The venlafaxine market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Venlafaxine industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on twenty-one industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The venlafaxine industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Venlafaxine Industry Overview - Global Venlafaxine Market Status Analysis - Major Regions Venlafaxine Market Status Analysis - Major Countries Venlafaxine Market Status and Analysis - Major Companies Venlafaxine Market Status and Analysis - Venlafaxine Industry Chain and Marketing Channels Analysis - Venlafaxine Industry Segment Market Analysis - Venlafaxine Industry Development Trend - Venlafaxine New Project Investment Feasibility Analysis - Global Venlafaxine Industry Research Conclusions Companies Mentioned - Abbott Laboratories - Amgen - Astellas - Astrazeneca - Bayer - Boehringer-Ingelheim - Bristol-Myers Squibb - Eisai - Eli Lilly Inc - Genentech - Glaxosmithkline - Johnson & Johnson - Kanghong Pharmaceutical - Merck - Novartis - Otsuka - Pfize - Roche Group - Sanofi-Aventis - Shuaike - Takeda For more information visit http://www.researchandmarkets.com/research/bzskl2/global
JNJ: 104.58 (-0.36), ABT: 45.58 (+0.38), MRK: 62.30 (-0.26), AMGN: 156.22 (+0.49), LLY: 69.42 (-0.51), BMY: 62.18 (+1.86), NVS: 95.48 (-0.64)
Merck (MRK) Stock Higher Today as It Speeds Plans to Submit New Drugs
at The Street - Mon Jan 12, 6:52AM CST
The drug maker accelerates plans to submit new drugs for hepatitis C and lung cancer for regulatory approval to close the gap with competitors in two lucrative segments.
MRK: 62.30 (-0.26)
Advaxis Provides 2014 Year-End Review and 2015 Outlook
GlobeNewswire - Mon Jan 12, 6:30AM CST
Multiple Clinical Milestones Anticipated in 2015 Involving Lm-LLO Cancer Immunotherapy Pipeline
ADXS: 12.09 (+0.79), MRK: 62.30 (-0.26), PETX: 18.67 (+0.07)
Merck accelerates regulatory submission plans in cancer and hepatitis
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 6:13AM CST
MRK: 62.30 (-0.26)
Bristol-Myers Checkpoint Inhibitor Prolongs Lung Cancer Patient Survival
at The Street - Mon Jan 12, 6:07AM CST
Lung cancer is a larger commercial market opportunity for Bristol's Opdivo and Merck's Keytruda.
MRK: 62.30 (-0.26), BMY: 62.18 (+1.86)
Merck Provides Update on Strategic Actions to Transform the Company and Build a Platform for Sustained Future Growth at the 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 12, 6:00AM CST
--Company Expects to Submit sBLA for KEYTRUDA in Mid-Year 2015 for Advanced Non-Small Cell Lung Cancer
JPM: 58.83 (-0.51), MRK: 62.30 (-0.26)
Neviah Genomics Achieves Key Development Milestone for PropheTox(TM) Bioassay for Early Prediction of Drug-Induced Liver Toxicity and Secures Additional Financing
Business Wire - Mon Jan 12, 6:00AM CST
Neviah Genomics announced today that it had discovered and experimentally validated a set of biomarkers for the early detection of chronic drug-induced liver toxicity. Based on these results, the company is moving toward the further development of its PropheTox(TM) Bioassay, targeting 2016 for its commercial introduction. Neviah Genomics was jointly established in 2012 by Merck Serono, the biopharmaceutical business of Merck, and Compugen, and is operating from MS Ventures' Israel Bioincubator in Yavne, Israel.
MRK: 62.30 (-0.26), CGEN: 9.26 (-0.03)
Bristol-Myers stops cancer trial early after Opdivo meets efficacy endpoint
Seeking Alpha - at Seeking Alpha - Sun Jan 11, 9:29PM CST
MDVN: 104.39 (+0.90), AZN: 70.79 (+1.35), MRK: 62.30 (-0.26), BMY: 62.18 (+1.86), CELG: 117.00 (+3.33), FPRX: 28.00 (+3.09)
5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 101.95 (-1.68), ACT: 272.28 (+3.60), AMGN: 156.22 (+0.49), RGLS: 18.90 (-0.43), EPZM: 17.49 (+0.01), ALKS: 68.61 (+3.47), HSP: 61.55 (-0.09), CELG: 117.00 (+3.33), JNJ: 104.58 (-0.36), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), ACHN: 14.64 (+0.08), MRK: 62.30 (-0.26), ABBV: 65.76 (-0.02), AGIO: 131.55 (+3.43), XLRN: 40.89 (-0.25), NVS: 95.48 (-0.64)
3 Ways Gilead Sciences, Inc. Could Still Be in Big Trouble
Sean Williams, The Motley Fool - Motley Fool - Sun Jan 11, 8:02AM CST
Arguably no biotech stock thrilled investors in 2014 more than Gilead Sciences . Gilead finished the year up 26%, about double the performance of the broad-market indexes, and the approval and exceptional launch of hepatitis C drugs Sovaldi and...
VRTX: 118.31 (-3.90), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), MRK: 62.30 (-0.26), AZN: 70.79 (+1.35), ABBV: 65.76 (-0.02)
3 Clinical-Stage Biotech Stocks with Explosive Upside Potential in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Jan 10, 1:07PM CST
Source: Flickr via Idaho National Laboratory. Biotech stocks have the uncanny ability to absolutely crush it following a positive clinical or regulatory catalyst. And this trend has been especially pronounced among standout clinical-stage...
BLUE: 101.95 (-1.68), DVAX: 18.58 (+0.87), HTGC: 14.70 (+0.12), NVAX: 6.41 (+0.10), PFE: 32.77 (+0.12), MRK: 62.30 (-0.26), AZN: 70.79 (+1.35), CLDN: 18.35 (-0.25), GSK: 42.93 (+0.13)
Can You Guess the Most Common Reason People Visit the Doctor?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 10, 6:14AM CST
Source: Flickr user Rusty Ferguson The Affordable Care Act, the health reform law better known as Obamacare, is quickly changing the medical care landscape. Gone are the days when insurers could deny coverage for preexisting conditions; now there...
MRK: 62.30 (-0.26), AMGN: 156.22 (+0.49), LLY: 69.42 (-0.51), BMY: 62.18 (+1.86)
Why Cubist Pharmaceuticals Inc. Stock Skyrocketed 33% in December
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 09, 1:02PM CST
What: Shares of Cubist Pharmaceuticals , a biopharmaceutical company focused on developing drugs to be used in the acute-care environment, skyrocketed 33% in December, based on data from S&P Capital IQ , after agreeing to be purchased by ...
CBST: 100.77 (+0.02), MRK: 62.30 (-0.26)
2015 Dogs of the Dow: 10 Dividend Stocks You Should Watch This Year
Dan Caplinger, The Motley Fool - Motley Fool - Fri Jan 09, 1:00PM CST
Source: Wikimedia Commons, courtesy Geo Swan. In recent years, investors have discovered the immense value of dividend-paying stocks, which have been one of the few reliable sources of portfolio income in a low-interest-rate environment that has...
KO: 42.64 (-0.39), GE: 23.98 (-0.05), PFE: 32.77 (+0.12), XOM: 90.33 (-1.77), INTC: 36.60 (-0.16), T: 33.49 (+0.09), MRK: 62.30 (-0.26), MCD: 93.01 (-0.20), CAT: 86.89 (-0.76), CVX: 105.88 (-2.33), MSFT: 46.60 (-0.59), VZ: 47.08 (+0.32), CSCO: 28.05 (+0.26)
FDA approves new blood thinner from Japanese drugmaker
AP - Fri Jan 09, 9:38AM CST
WASHINGTON (AP) — The Food and Drug Administration has approved a new blood thinner from a Japanese drugmaker to reduce stroke and blood clots in patients with a common irregular heartbeat.
JNJ: 104.58 (-0.36), PFE: 32.77 (+0.12), MRK: 62.30 (-0.26), BMY: 62.18 (+1.86)
